Novo Nordisk Q3 Earnings Buoyed By Higher Diabetes And Obesity Care Sales

Novo Nordisk A/S NVO Q3 sales increased 15% Y/Y (15% at CER) to DKK 35.62 billion.
Diabetes and Obesity care sales drove global sales as GLP-1 sales increased by 31% at CER, Obesity care sales by 82%, and insulin sales by 4%, reflecting the uptake of Ozempic & Rybelsus and market expansion and the launch of Wegovy in the U.S.
Also Read: Novo Nordisk Settles Insulin Pricing Lawsuit For $100M.
Biopharm sales decreased by 2%. Sales in International Operations increased 15% (14% CER) at DKK 18.34 billion, and sales in North America Operations increased by 16% (17% at CER) to DKK17.28 billion.
The gross margin remained almost constant at 83%, while the operating margin increased from 41.4% to 42.8%.
Novo Nordisk initiated Phase 3 trial with oral semaglutide 50 mg to treat obesity and ziltivekimab in cardiovascular disease during Q3.
Net profit increased by 18% to DKK 12.12 billion, and EPS increased by 19% to 5.27 DKK.
Guidance: The Company expects FY21 operating profit growth of 12% - 15% at CER, versus 9% - 12%, expected earlier.
Related: Novo Nordisk Boosts FY21 Outlook After Solid Q3 Sales.
Price Action: NVO shares are up 2.47% at $112.77 during the premarket session on the last check Wednesday.

Earnings Calendar